Trem2-deficiency aggravates and accelerates age-related myelin degeneration

Tyler J McCray1, Logan M Bedford1, Stephanie J Bissel1,2

  • 1Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA.

PubMed

Insights

The study reveals that the TREM2 receptor is crucial for repairing age-related myelin damage. Its deficiency accelerates degeneration and impairs microglial cells, highlighting TREM2

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Aging is the primary risk factor for neurodegenerative diseases.
  • Myelin degeneration is an early pathological sign in aging and neurodegeneration.
  • Microglia, particularly via TREM2 (triggering receptor expressed on myeloid cells 2), regulate myelin dynamics.

Purpose of the Study:

  • To investigate the role of TREM2 in age-related myelin degeneration.
  • To understand how TREM2 influences microglial function in white matter repair.

Main Methods:

  • Analysis of age-related myelin degeneration in the striatum of wild-type and Trem2-deficient mice.
  • Assessment of microglial recruitment, phagocytosis, OPC differentiation, and ER stress responses.

Main Results:

  • Trem2 deficiency exacerbates and accelerates age-related myelin degeneration.
  • TREM2 is essential for recruiting reparative glia and promoting oligodendrocyte precursor cell (OPC) differentiation.
  • TREM2 mediates efficient phagocytosis of myelin debris and modulates ER stress to prevent microglial dysfunction.

Conclusions:

  • TREM2 plays a vital role in mitigating age-related myelin degeneration.
  • Dysfunctional microglia, due to insufficient TREM2 signaling, can contribute to neurodegenerative pathology.
  • Targeting TREM2 pathways may offer therapeutic strategies for age-related white matter diseases.

Related Concept Videos

Nervous Tissue: Myelin01:25

Nervous Tissue: Myelin

The myelin sheath is a multilayered lipid and protein covering that insulates the axon of a neuron, enhancing the speed of nerve impulse conduction. Axons without this sheath are referred to as unmyelinated. Two types of neuroglia, Schwann cells in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS) are responsible for producing myelin sheaths.
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...